Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S. Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023 Aug;89(2):235-242. doi: 10.1016/j.jaad.2023.04.027. Epub 2023 Apr 23. PMID: 37094653.


Related Posts